Ultrasound-detected gastric changes related to zolbetuximab-induced emesis: a case series.

ABSTRACT:

Background

Zolbetuximab prolongs survival in patients with claudin18.2 (CLDN18.2)-positive gastric cancer (GC) and gastroesophageal junction cancer. However, it is associated with an increased risk of emesis, and its underlying mechanism remains unclear.

Case presentation

This report presents three cases of advanced GC that underwent abdominal ultrasonography (US) during zolbetuximab administration. In two patients with primary gastric lesions, severe nausea occurred during the first treatment cycle. US findings revealed increased echogenicity of the submucosal layer, enhanced layer stratification, and increased blood flow signals, which improved as the emesis subsided. During the second cycle, emesis was milder, and US findings revealed only slight changes. In the third pat

SUBMITTER: Harada K 

PROVIDER: S-EPMC12699232 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature